A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy

MLA

Keigo Makino, et al. “A Randomized, Double‐blind, Phase II Study of Oral Histone Deacetylase Inhibitor Resminostat plus S‐1 versus Placebo plus S‐1 in Biliary Tract Cancers Previously Treated with Gemcitabine plus Platinum‐based Chemotherapy.” Cancer Medicine, vol. 10, no. 6, Mar. 2021, pp. 2088–99. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e211a5d95321516773904b1b29a4a68c&authtype=sso&custid=ns315887.

APA

Keigo Makino, Hiroshi Ishii, Akihito Tsuji, Masato Ozaka, Makoto Ueno, Shingo Kobayashi, Manabu Muto, Daisuke Sakai, Yoshito Komatsu, Masafumi Ikeda, Nobumasa Mizuno, Akira Fukutomi, Toshikazu Moriwaki, Yousuke Nakai, Masayuki Furukawa, Takeshi Kajiwara, Akio Katanuma, Chigusa Morizane, Yuji Negoro, … Noriko Nemoto. (2021). A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy. Cancer Medicine, 10(6), 2088–2099.

Chicago

Keigo Makino, Hiroshi Ishii, Akihito Tsuji, Masato Ozaka, Makoto Ueno, Shingo Kobayashi, Manabu Muto, et al. 2021. “A Randomized, Double‐blind, Phase II Study of Oral Histone Deacetylase Inhibitor Resminostat plus S‐1 versus Placebo plus S‐1 in Biliary Tract Cancers Previously Treated with Gemcitabine plus Platinum‐based Chemotherapy.” Cancer Medicine 10 (6): 2088–99. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e211a5d95321516773904b1b29a4a68c&authtype=sso&custid=ns315887.